These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 28687231)

  • 1. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
    Albers FC; Price RG; Smith SG; Yancey SW
    J Allergy Clin Immunol; 2017 Nov; 140(5):1464-1466.e4. PubMed ID: 28687231
    [No Abstract]   [Full Text] [Related]  

  • 2. Reslizumab as add-on therapy in patients with refractory asthma.
    Virchow JC; McDonald M; Garin M; Korn S
    BMJ Open Respir Res; 2020 Apr; 7(1):. PubMed ID: 32273395
    [No Abstract]   [Full Text] [Related]  

  • 3. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy.
    Howarth P; Chupp G; Nelsen LM; Bradford ES; Bratton DJ; Smith SG; Albers FC; Brusselle G; Bachert C
    J Allergy Clin Immunol; 2020 Jun; 145(6):1713-1715. PubMed ID: 32084443
    [No Abstract]   [Full Text] [Related]  

  • 5. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
    Strauss RA; Jawhari N
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
    [No Abstract]   [Full Text] [Related]  

  • 6. For patients with chronic asthma not controlled with inhaled corticosteroids alone, long-acting β-agonists are associated with fewer exacerbations than leukotriene receptor agonists.
    Colice G
    Evid Based Med; 2014 Oct; 19(5):174. PubMed ID: 24917602
    [No Abstract]   [Full Text] [Related]  

  • 7. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
    Han S; Kim S; Kim H; Suh HS
    Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.
    Terashima T; Shinozaki T; Iwami E; Nakajima T; Matsuzaki T
    BMC Pulm Med; 2018 Mar; 18(1):53. PubMed ID: 29587693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 11. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab for Treatment of Severe Eosinophilic Asthma: A 5-Year Real-World Experience.
    Loli-Ausejo D; Perdomo G; Mascaró B; Martínez-Olondris P; Sánchez-Fernández MC; Mullol J; Valero A; Arismendi E; Bobolea I
    J Investig Allergol Clin Immunol; 2023 Jun; 33(3):209-210. PubMed ID: 36820628
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mepolizumab use: Post-approval academic practice experience.
    Benjamin MR; Bochner BS; Peters AT
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):126-128. PubMed ID: 29653234
    [No Abstract]   [Full Text] [Related]  

  • 15. Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma.
    d'Ancona G; Kavanagh JE; Dhariwal J; Hearn AP; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Jackson DJ; Kent BD
    Allergy; 2021 Jul; 76(7):2238-2241. PubMed ID: 33432682
    [No Abstract]   [Full Text] [Related]  

  • 16. [PHARMACOGENETIC MARKERS OF THE EFFECTIVENESS OF TREATMENT OF CHILDREN WITH ATOPIC BRONCHIAL ASTHMA.].
    Balabolkin II; Bulgakova VA
    Eksp Klin Farmakol; 2016; 79(11):35-40. PubMed ID: 29791107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
    Weir E; Paton J
    J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
    [No Abstract]   [Full Text] [Related]  

  • 19. Asthma in 2016: reassured about the old, excited about the new.
    Sood S; Castro M
    Lancet Respir Med; 2016 Dec; 4(12):937-939. PubMed ID: 27890498
    [No Abstract]   [Full Text] [Related]  

  • 20. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
    Cormier M; Chaboillez S; Lemiere C
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.